Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MedWellAI (MWAI) EBITDA (2016 - 2026)

MedWellAI has reported EBITDA over the past 11 years, most recently at -$265417.0 for Q4 2025.

  • Quarterly EBITDA rose 12.88% to -$265417.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$350630.0 through Dec 2025, up 82.88% year-over-year, with the annual reading at -$761736.0 for FY2025, 91.6% up from the prior year.
  • EBITDA was -$265417.0 for Q4 2025 at MedWellAI, up from -$317727.0 in the prior quarter.
  • Over five years, EBITDA peaked at $11.9 million in Q2 2021 and troughed at -$16.3 million in Q1 2021.
  • The 5-year median for EBITDA is -$333772.0 (2021), against an average of -$984359.9.
  • The largest YoY upside for EBITDA was 5145.71% in 2021 against a maximum downside of 4747.28% in 2021.
  • A 5-year view of EBITDA shows it stood at -$331865.0 in 2021, then tumbled by 84.01% to -$610649.0 in 2022, then surged by 45.03% to -$335679.0 in 2023, then grew by 9.24% to -$304648.0 in 2024, then increased by 12.88% to -$265417.0 in 2025.
  • Per Business Quant, the three most recent readings for MWAI's EBITDA are -$265417.0 (Q4 2025), -$317727.0 (Q3 2025), and $1.0 million (Q2 2025).